2017 OHSU Commercialization Conference

2017 OHSU Commercialization Conference

Registration is closed. 

Maximum capacity has been reached.


The 2017 Commercialization Conference connects OHSU innovators with investors, industry partners, and community collaborators to help build a vibrant regional hub for innovative technology. Join OHSU Technology Transfer and Business Development for a day of sessions, startup and collaboration pitches, industry insights, and successful collaboration stories.

We have a great line up of speakers and panelists, including our two keynote speakers, William Ruh, the CEO of GE Digital and Gerry Langeler, managing director of OVP Venture Partners.

OHSU Technology Transfer and Business Development celebrates the fifth year of our signature conference, formerly the Startup Symposium, by expanding the framework to include startup and established enterprises.



Opening Remarks

Abhijit BanerjeeAbhijit Banerjee, Ph.D., M.B.A.
Senior Director, Business Development, OHSU

Dr. Banerjee oversees the Business Development function at OHSU as an interface between OHSU investigators and the pharmaceutical/biotech industry, helping develop strategic alliances with industry, foundations & government. Dr. Banerjee is also responsible for supporting OHSU's startup companies and participates in strategic initiatives related to commercialization of OHSU's assets and technologies. Recently he was invited to join the GE Ventures Advisory Council. Prior to joining OHSU Dr. Banerjee was a Senior Consultant with Deloitte and a Strategic Alliance Manager at Pfizer. He has worked as a researcher at Imperial College in London and at Boston University. Dr. Banerjee received his Ph.D. from the India Institute of Chemical Biology in India and his M.B.A. from Suffolk University in Boston, completing his post-doctoral training at the University of Wisconsin-Madison.

Dan DorsaDaniel Dorsa, Ph.D.
Senior Vice President for Research, OHSU

Daniel Dorsa, Senior Vice President for Research, leads the research mission at OHSU. Dorsa's research has focused on understanding the molecular mechanisms that underlie the effects of steroid hormones such as estrogen in the brain and nervous system. After an extensive career at the University of Washington, he joined OHSU in 2001 to spearhead the expansion of research at OHSU made possible by the Oregon Opportunity. Since then, he has presided over the immense growth of research at OHSU, which garnered $400 million in outside funding in 2017. His purview has included, in addition to administrative responsibilities, the recruitment of top faculty, building state-of-the-art research facilities, and developing corporate and industry relationships. 

Elena AndresenElena Andresen, Ph.D.
Executive Vice President and Provost, OHSU

Dr. Andresen served as Interim Provost from October 1, 2016 until being appointed Executive Vice President and Provost June 1, 2017. She previously served as Interim Dean of the OHSU-PSU School of Public Health between May 2014 and September 2016, and continues as professor of Epidemiology in the new School. Dr. Andresen joined OHSU in 2011 after serving as professor and the founding chair of the Department of Epidemiology and Biostatistics at the University of Florida College of Public Health and Health Professions. Elena is an experienced epidemiologist (Ph.D., University of Washington, 1991) who received additional training in health services research. Her collaboratively funded research history includes the National Institutes of Health, the Agency for Healthcare Research and Quality, the Department of Veterans Affairs, and the Centers for Disease Control and Prevention. Her recent work has been directed at aging and the public health outcomes of disability across the lifespan, and health services outcomes research methods and measures. Dr. Andresen is the PI of the Oregon Office on Disability and Health at OHSU.

Brendan RauwBrendan Rauw, M.B.A., C.L.P.
Vice President, Technology Transfer and Business Development, OHSU 

Brendan Rauw is Vice President of Technology Transfer and Business Development. He is responsible for advancing commercialization of OHSU's intellectual property, increasing industry research collaborations, and developing strategic alliances. Prior to joining OHSU, Brendan was Associate Vice Chancellor and Executive Director of Entrepreneurship at UCLA, and the founding CEO of Westwood Technology Transfer, an independent entity that oversees commercialization at UCLA. Previously, he held leadership positions at Columbia Technology Ventures, KAUST, and the Boston Consulting Group. He also worked in corporate and business development with Genzyme and Celator Pharmaceuticals. Brendan received his undergraduate degree from Harvard College and M.B.A. from Harvard Business School.

Opening Keynote

William Ruh

William Ruh, M.S.
Chief Executive Officer of GE Digital, Senior Vice President and Chief Digital Officer of GE
GE Digital, a $6 billion business of GE, provides premier digital software solutions and services for the industrial world. GE Digital supports customers globally with a broad range of Industrial Internet applications, from asset performance management, operations optimization and brilliant manufacturing to platform-as-a-service, cloud and cyber security. As the CDO, Ruh is responsible for global IT as well as creating GE's Digital Thread a next generation system for streamlining design, manufacturing and support processes. Ruh joined GE in 2011 to establish its Industrial Internet strategy and to lead the convergence of the physical and digital worlds within GE globally. In this role, he focused on building out advanced software and analytics capabilities, as well as driving the global strategy, operations and portfolio of software services across all of GE's businesses. During his tenure, Ruh led the charge to develop the first cloud-based platform for the industrial world. He also played an instrumental role in establishing the Industrial Internet Consortium by bringing together government, academia and industry leaders for setting the standards, best practices and processes for the Industrial Internet. Prior to this, Ruh was vice president at Cisco where he held global responsibility for developing advanced services and solutions. A 30-year veteran of the software and internet industries, Ruh has held executive management positions at Software AG, Inc., The Advisory Board, The MITRE Corporation and Concept 5 Technologies. Ruh is an accomplished author and a frequent speaker on such topics as emerging business models, cloud computing, analytics, mobile computing, agile development, large scale distributed systems, and M2M communications. He earned a bachelor's and master's degrees in Computer Science from California State University, Fullerton.


Executive panel: Breakthrough Innovations Transforming Healthcare

Brian Druker

Brian Druker, M.D.
Director, Knight Cancer Institute, OHSU and Associate Dean, School of Medicine — Oncology, OHSU

Dr. Druker's research is focused on translating knowledge of molecular pathogenesis of cancer into specific therapies, and investigating optimal use of these molecularly-targeted agents. His preclinical studies led to the development of imatinib (Gleevec) for chronic myelogenous leukemia; he spearheaded highly successful clinical trials of imatinib, which led to FDA approval in record time, resulting in a paradigm-shift in cancer treatment from non-specific chemotherapy to highly-targeted therapeutic agents. Dr. Druker also serves as a JELD-WEN Chair of Leukemia Research and a Howard Hughes Medical Institute investigator.

Harry GlorikianHarry Glorikian, M.B.A.
General Partner, New Ventures Funds

Harry is currently a General Partner at New Ventures Funds (NV). Before joining NV Funds, he served as an Entrepreneur In Residence to GE Ventures –New Business Creation Group. He currently serves on the board of GeneNews Ltd. He also serves on the advisory board of Evidation Health (a digital health startup launched with support from GE Ventures), and several other companies. He is also a co-founder and an advisory board member of DrawBridge Health (a revolutionary diagnostics startup launched with support from GE Ventures). Harry holds an MBA from Boston University and a bachelor's degree from San Francisco State University. Harry has addressed the NIH, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston Globe, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many others.

Jay HillJohn C. Hill, Jr., M.S.E.E. 
General Manager of Operations and Chief Operating Officer of Imaging, GE Healthcare

Jay Hill is GM, Operations and COO for GE Healthcare's Imaging business. He is a 25 year veteran of GE, with engineering and leadership roles in Power, Industrial Security fields. He has led new product development, R&D and strategy. He joined GE Healthcare in 2012 as Chief Technology Officer for the x-ray-based product portfolio. Jay holds a B.S.E.E. from SUNY, Buffalo and an M.S.E.E. from RPI. He is a board member of industry group BioForward, Inc. and GE Executive Sponsor for Olin College. Jay lives in Wisconsin with his wife and two children and is an avid musician.

Brian LawrenceBrian L. Lawrence, Ph.D.
Senior Vice President and Chief Technology Officer, Hill-Rom

Brian is the Chief Technology Officer of Hill-Rom. He is responsible for all new product development and technology innovation across Hill-Rom's portfolio of products including patient support systems, information technology systems, surgical consumables and infrastructure, patient monitoring and diagnostic solutions, and respiratory care devices. Lawrence joined Hill-Rom in December of 2010 from GE Healthcare where he was CTO for Life Support Solutions, and he held a variety of other executive leadership positions during his career with GE Healthcare. Before joining GE, Lawrence was President and CEO of Extend Optical Systems Corporation and prior to that he was the Vice President and CTO of Molecular OptoElectronics Corporation. Lawrence holds a Bachelor's and a Master's degree from the Massachusetts Institute of Technology and a Ph.D. from the Center for Research and Education in Optics and Lasers (CREOL) at the University of Central Florida. He has published 24 articles in peer reviewed journals, given over 50 conference presentations including keynote, invited, and plenary talks, and has 48 issued U.S. patents.

Nick PliamNick Pliam, M.D., Ph.D.,
Venture Partner, Decheng Capital

Nick Pliam is a Venture Partner at Decheng Capital. He began his healthcare investment career at Bay City Capital in 2006, focusing on medical technology and serving on the boards Nevro Corporation (NYSE: NVRO), Aragon Surgical (acquired by Aesculap) and IDev Technologies (acquired by Abbott Laboratories). He is currently a director of China based Ketai Medical and CardiMED Ltd. Nick received an MD from Dartmouth Medical School and a PhD in Endocrine Physiology from UCSF, following German literature studies at UC Berkeley. He trained in general surgery at UCSF and completed orthopedic surgical training at Stanford University.

Role of Molecular Imaging in the Era of Personalized Medicine

Joe GrayJoe W. Gray, Ph.D.
Director, Center for Spatial Systems Biomedicine, OHSU and Associate Director for Biophysical Oncology, Knight Cancer Institute, OHSU

Dr. Joe W. Gray is the Director, OHSU Center for Spatial Systems Biomedicine;and Associate Director for Biophysical Oncology, Knight Cancer Institute. He applies 'omic and imaging technologies to elucidate mechanisms by which cancers become resistant to treatment and uses this information to develop therapeutic strategies to more durably control advanced cancers. He has more than 460 publications and 80 US patents. Major awards include the E.O. Lawrence Award, U.S. Department of Energy; Curt Stern Award, American Society for Human Genetics; the Alfred G. Knudson Award in Cancer Genetics, National Cancer Institute and Election to the National Academy of Medicine.

Christine LorenzChristine H. Lorenz, Ph.D.
Vice President, Research and Clinical Collaborations, Siemens Medical Solutions USA

Dr. Christine Lorenz is currently Vice President, Research and Clinical Collaborations, Siemens Medical Solutions USA, Inc., with global responsibility for innovation and intellectual property management in Molecular Imaging. In this role she leads both internal research as well as external research with healthcare institutions to expand the value of molecular imaging and establish new clinical indications. She has a Ph.D. in biomedical engineering, as well as an M.B.A. She has been with Siemens since 2000, and has held a series of positions in the UK, Germany, and in the USA in multiple areas of medical imaging. Previously, she was on the faculty at Washington University in St. Louis where she also worked to develop new medical imaging applications.  

William RooneyWilliam Rooney, Ph.D.
Director and Professor, Advanced Imaging Research Center, OHSU

Dr. Rooney earned his Ph.D. from the Department of Chemistry at the State University of New York at Stony Brook. After a brief stint as a Research Scientist in industry, he completed an NIH NRSA post-doctoral fellowship in neuroimaging at the Department of Radiology/University of California San Francisco and was promoted to Assistant Professor of Radiology (UCSF). Rooney later joined the Chemistry Department of Brookhaven National Laboratory as faculty, and served as Head of BNL's High-Field MRI Laboratory from 2003-2005. Dr. Rooney joined the Advanced Imaging Research Center of OHSU in 2005, where he holds his primary appointment now as Director and Senior Scientist (Professor). Dr. Rooney is a member of OHSU graduate faculty in Neuroscience. Research in Rooney's group is focused on the development, application, and validation of quantitative magnetic resonance imaging and spectroscopy to characterize tissue structure and function. He also is experienced in advanced instrumentation approaches including optical tracking and real-time motion correction in MRI, development and integration of a solid-state PET detector in a high-field MRI instrument, and electronic referencing of MRI receivers.

Carsten SchultzCarsten Schultz, Ph.D.
Chair, Department of Physiology and Pharmacology, OHSU and Group leader and scientist, European Molecular Biology Laboratory

Carsten studied chemistry in Germany. After his PhD he joined the lab of Roger Tsien at UC San Diego. Carsten started his own lab back in Bremen Germany and in 2000 became a group leader at the Max-Planck-Institute for Molecular Physiology. In 2001, he moved to the EMBL in Heidelberg where he was granted tenure in 2008. The Schultz Group develops tools for imaging and manipulating cellular enzyme activities in intact cells and tissues with a particular emphasis on lipid signaling. The group is mainly interested in visualizing entire signaling networks and in chemical and optical methods for manipulating cells in a disease context. The latter includes cancer, diabetes and the hereditary disease cystic fibrosis.

Pharma's Transition from Internal R&D to External Collaborations

Kanad DasKanad Das, Ph.D.
Director, Business Development and Licensing, Merck

In his current role as Director, Business Development and Licensing at Merck, Kanad is responsible for the search and evaluation of assets up to Human proof of concept on the West Coast. Currently focusing on Immuno-Oncology, Ophthalmology and Metabolic diseases, he interacts with start-ups and academia to find assets to bolster Merck's pipeline. Prior to Merck, Kanad was the Assoc. Director, Alliance Management and Partnering at Stanford University's SPARK Program where he led the commercialization efforts of some of Stanford's discoveries. Kanad has previous worked for KAI Pharmaceuticals and Genentech. He received his Ph.D. from UMass., Amherst and his B.Sc. from UC Berkeley.

Melissa FitzgeraldMelissa M. Fitzgerald, Ph.D.
Senior Director of Global Scouting — San Diego, Pfizer

As the Senior Director, Global Scouting—San Diego for Pfizer's External Research &Development Innovation (ERDI) group, Melissa leads scouting efforts in the Southwest region of North America, and helps expand and manage partnerships with key academic institutes and start-up companies in areas of scientific interest to Pfizer Worldwide Research and Development and the Pfizer Emerging Science Fund. Melissa brings to ERDI's Global Scouting team her enthusiasm for promoting innovation, gained through fifteen years of research and corporate development experience in the San Diego Life Sciences eco-system. She held positions of increasing responsibility at Dura Pharmaceuticals (acquired by Elan Pharmaceuticals), Derm Tech International, and UC San Diego's Technology Transfer office. Melissa was also an Associate Director-Business Development at Amylin Pharmaceuticals. In 2009, Melissa moved to UC San Diego to help found and launch UC San Diego's new Institute for Genomic Medicine, and then moved to the UCSD Technology Transfer Office for a second term prior to joining Pfizer in 2011. 

Nick SaccomanoNick Saccomano, Ph.D.
Chief Scientific Officer, Array Biopharma

Nick Saccomano is currently the Chief Science Officer of Array Biopharma located in Boulder, Colorado. He began his professional career at Pfizer. In his 25 years in that organization he held positions of increasing scope including Senior Vice President with responsibility for strategic alliances and global technology platforms. During the time between Pfizer and Array, Nick worked at Bend Research as CSO and subsequently SomaLogic as CTO. He received his Ph.D. from Columbia University in Chemistry.

Peter SandorPeter Sandor, M.D., M.D.S., M.B.A.
Vice President and Head of Oncology Therapeutic Area in Marketing Strategy, Astellas

In this role, Peter provides commercial leadership for project's within the oncology therapeutic area and plays an integral role in the expansion of Astellas's presence in oncology. Peter has 20 years of progressive marketing experience. He was recently the Vice President, Global Marketing Oncology at Amgen responsible for the successful realization of the commercial potential for Amgen's oncology assets. Prior to Amgen, he has held different positions at Bayer Healthcare, including Head of Strategy and Portfolio Management Specialty Medicine, Commercial Development and Life Cycle Management Global Oncology. He also worked for Berlex Laboratories as the lead of the global launch team for a key oncology compound, and held multiple marketing roles with Schering AG in Germany and Hungary.

Women's Contributions to Innovation in Science and Business

Jennifer FoxJennifer Fox, Ph.D.
Executive Director, Oregon Translational Research and Development Institute (OTRADI)
Dr. Fox is the Executive Director of OTRADI and the OTRADI Bioscience Incubator. OTRADI is a state-funded non-profit that fuels Oregon's bioscience industry by translating innovative research into products and incubating companies that benefit health and wellness and create high-wage jobs for Oregon. Since founding OTRADI in 2008, Dr. Fox has helped to generate $14M in grant funding and $3M in revenue. In 2013, OTRADI opened Oregon's only bioscience-focused incubator - the OTRADI Bioscience Incubator, which is now home to 17 startup companies, developing medical devices, diagnostics, therapeutics, digital health and healthcare IT products.

Sandy LeachmanSancy Leachman, M.D., Ph.D.
Professor and Chair, Department of Dermatology, OHSU

Dr. Leachman is a physician-scientist who chairs the Department of Dermatology at OHSU and is the director of the Melanoma Research Program at the OHSU Knight Cancer Institute, an NCI-designated Comprehensive Cancer Center. Prior to joining OHSU in 2013, Dr. Leachman was director of the Melanoma and Cutaneous Oncology Program in the Huntsman Cancer Institute at the University of Utah, a professor in the Department of Dermatology, and member of the Imaging, Diagnostics, and Therapeutics Program and the Cancer Control and Population Sciences Program. Dr. Leachman earned an M.D., Ph.D. at the University of Texas Southwestern Medical School, 1993 and her B.A. at University of Texas at Austin Plan II, 1985. Her residency was at Yale-New Haven Hospital (dermatology) in New Haven, CT; she completed a Fellowship in cutaneous oncology at Yale University School of Medicine, and is certified by the American Board of Dermatology.

Usha PillaiUsha Pillai, Ph.D., P.M.P., M.S.
Founder and President, Aria Management Consulting, LLC.

As the Founder and President of Aria Management Consulting, LLC, Dr. Pillai specializes in strategy, critical thinking, change management, and project/program management, and M&A integration. She is a senior consultant for Leading Women, an organization dedicated to women's leadership development. Dr. Pillai serves on the Connecticut Bioscience Growth Council, the Advisory Board of the Biotechnology Academic and Career Pathway (BioPath), and the Garde Arts Center. Prior to founding Aria Management Consulting, Dr. Pillai held several positions of increasing responsibility and complexity at Pfizer, Inc. She is a certified Project Management Professional (PMP). She holds a bachelor's degree in pharmacy; an Executive Masters in Technology Management from RPI; and a Ph. D. in Pharmaceutical Sciences.

Christi ShawChristi Shaw, M.B.A.
Senior Vice President and President, Lilly Bio-Medicines

For Christi Shaw, “More Moments for More Memories” isn’t just a mantra – it’s a personal and professional mission. She leads through the lens of innovation, integrity and inclusion and brings an unwavering commitment to addressing the evolving needs of patients, in collaboration with healthcare professionals, advocacy groups, payers and policy makers. Shaw has held positions of increasing influence and authority across the bio-pharmaceutical industry over three decades, including leadership positions at Eli Lilly and Company, Johnson & Johnson and Novartis. She re-joined Lilly in 2017 as Senior Vice President and President of Lilly Bio-Medicines, the company’s broadest therapeutic portfolio.

Company Pitches

Andrew Watson

Andrew Watson, Ph.D., C.L.P.
Senior Director, Technology Transfer, OHSU
Dr. Watson manages the licensing, commercialization, intellectual property protection, and industry collaborations aspects for OHSU's Technology Transfer and Business Development office. He is involved in the day-to-day management of the office and technology transfer staff as well as having significant input into preparation and management of departmental budgets. He is also involved in developing and implementing university policies, providing leadership in developing strategies for corporate collaboration, advising on IP contract provisions, actively negotiating complex business agreements, and serving as an OHSU spokesperson for matters relating to IP, commercialization and economic impact of OHSU research. He has authored several scientific publications and technology transfer articles, and also has been an invited speaker at both scientific and technology transfer conferences. Dr. Watson received his B.S. from Whitworth University and his Ph.D. in Biomedical sciences with a research emphasis in immunology and infectious diseases from the State University of New York.

David HuangDavid Huang, M.D., Ph.D.
Founder, GoBiquity Mobile Health

Dr. Huang is the Peterson professor of Ophthalmology, professor of Biomedical Engineering, and Director of the Center for Ophthalmic Optics and Lasers at OHSU. Dr. Huang is a co-inventor of optical coherence tomography (OCT), the most common imaging procedure in ophthalmology, with an estimated 30 million patients imaged per year. His seminal article on OCT, published in Science in 1991, has been cited more than 10,000 times. He leads an active NIH-supported research program on the ophthalmic applications of OCT and OCT angiography. He holds patents in the areas of OCT, OCT angiography, laser therapeutic devices, and mobile diagnostic tests. He is a founder of Gobiquity Mobile Health, Inc., a maker of mobile diagnostic apps for both professional and home use. Dr. Huang has received the Champalimaud Vision Award, ARVO Friedenwalk Award, AAO Senior Achievement Award, NAE Russ Award, and Epstein Award.

Matt JohnsonMatthew Johnson
General Manager and Executive Officer, APDM Wearable Technologies

Matt was hired in late 2010 to help build out the commercial operations at APDM Wearable Technologies, focused on the sales and marketing. In the early years he developed APDM's product branding, company messaging, and domestic and international sales strategies; all while answering every customer's emails and phone calls. Lately, he wised up by surrounded himself with highly capable employees to amplify APDM's growth. Matt, like many of his colleagues at APDM, is a graduate of Portland State University.

Frank OliverFrank Oliver
Chief Executive Officer, Server Dome

Frank Oliver is a technology entrepreneur. In his career he has served as chief engineer, chief scientist, CTO and CEO of a variety of small businesses and start-ups.  Currently Frank is working to commercialize the ServerDome technology licensed from OHSU. When he is not working he can usually be found assembling small plastic interlocking blocks.

Mark SlifkaMark Slifka, Ph.D.
President and Chief Scientific Officer,
Najít Technologies, Inc.
Dr. Slifka is a Professor at OHSU in addition to being the President and CSO of Najít Technologies, Inc. (NTI), a local vaccine development company. He has published over one hundred articles in leading journals such as Immunity, Nature, Nature Immunology, Nature Medicine, and the New England Journal of Medicine. Dr. Slifka has served on committees for the NIH, HHMI, CDC, IOM, and the FDA in addition to serving on committees for a number of international health agencies. His academic studies on immunological memory led to the discovery of new approaches to vaccine development and NTI is currently preparing vaccines against diseases of global importance including yellow fever, dengue, chikungunya, and zika. 

Erik TuckerErik Tucker, Ph.D.
Co-Founder and Chief Operating Officer, Aronora

Dr. Tucker is Co-Founder and COO of Aronora, an emerging biotechnology company and OHSU spin-off. He is an inventor of several pioneering drug candidates that are currently under development at Aronora to treat important blood clotting diseases, including stroke and heart attack. He completed a B.S. at the University of Oregon and Ph.D. in Biomedical Engineering at OHSU. Dr. Tucker has authored more than 30 scientific publications, and was one of the Portland Business Journal's Forty under 40 class of 2015. He has raised over $21 million in non-dilutive NIH SBIR funding to help advance Aronora’s innovative therapeutic candidates into the clinic.

Marketing and Branding: Go-to-Market Strategies for Innovations

Chris ConleyChris Conley
Partner, Heritage Partners

Chris is a Partner at Heritage Partners, an executive search and advisory consulting group. She builds teams for life science VC backed start-up, emerging and growth companies. She has worked exclusively in the life science industry for 18 years providing strategic advisory to position companies for greater success. Prior to joining HPI she ran her own consulting firm for 9 years after launching a Life Science Practice for a national executive search firm. She held positions in leadership, marketing and management consultancy. Early in her career she was a private corporate flight attendant for HRH Prince Talal bin Abdul Aziz of the Saudi Royal family promoting AGFUND and UNICEF's Special Envoy for socioeconomic development in the Middle East.

Christine DumasChristine Dumas
Consumer health and lifestyle reporter/Strategic consumer trends advisor/Author

Dr. Christine Dumas is a consumer, health and lifestyle reporter, strategic consumer trends advisor and author. Since 1996, Christine has covered the lifestyle, consumer affairs, health and wellness space and her stories have appeared on NBC's Today: Weekend Edition and Weekend Live on FOX, and she has made guest appearances on both The Oprah Winfrey Show and The View. In addition to her clinical training, she holds a Bachelor of Arts degree in Economics from UCLA. As an expert in consumer trends, Dr. Dumas has advised domestic and multi-national brands on their media relations strategy, product positioning, and tactical outreach. Dr. Dumas has been the national spokesperson for Fortune 500 company media campaigns and she served as a senior adviser to the Center for Health Transformation in Washington, DC. 

Dennis FordDennis Ford
Founder & Chief Executive Officer, Life Science Nation
Dennis Ford is an entrepreneur and author with expertise in sales, marketing, and business development. He has spent most of his career launching new companies. Over the last decade, he has worked extensively with global alternative investors interested in high-growth early-stage technologies. His expertise encompasses using database subscription services to create business solutions and using the Internet to create an interactive dialog between buyers and sellers. He is a big proponent of using profiling and matching technology to find that all-important business fit in the marketing and selling process. Before LSN, Dennis was the President and CEO of Brighton House Associates (BHA). BHA was launched in order to improve the way hedge fund and private equity fund managers raised capital and marketed their funds to investors.Ford is the author of The Peddler’s Prerogative and The Fund Manager’s Marketing Manifesto, two well-received sales and marketing books. His latest book is The Life Science Executive’s Fundraising Manifesto.

Ann MukherjeeAnn Mukherjee, M.B.A.
Chief Global Marketing Officer, SC Johnson

After very successful careers at Kraft and PepsiCo, Ann joined SC Johnson as its first ever Global Chief Marketing Officer. She is committed to the Johnson Family's mission and purpose of making life better for future generations. Ann is an accomplished storyteller and motivational teacher and inspires everyone she leads to "Transform Tomorrow Today." She served on public and private boards and is currently on the Global Board for the Effie's organization and the Board of Trustees of the Marketing Accounting and Standards Board (MASB).


Creating Partnerships with Investors

James BurdenJames E. Burden, J.D.
Co-Founding Principal, Par Equity USA

James E. Burden, a California lawyer, has over 40 years experience in corporate finance, corporate and transaction law practice, and management and business operations. Dorset is a co-founding principal of Par Equity USA, expanding Par Equity in the UK to the United States. The first focus area will be the Par Transatlantic HealthTech Fund I, which will invest in digital health technology companies with proprietary products that are, or are close to, generating revenue where transatlantic expansion can accelerate the next stage of their growth. HealthTech includes patient monitoring, wearable medical devices, robotics, diagnostics and imaging, secure data management and genomic screening. The Par Fund will focus on companies suitable for expansion from the U.K. to the U.S. or expanding from the U.S. to the U.K. Transatlantic expansion is a milestone that can trigger a valuation inflection and significant returns to investors.

Chelsea HewittChelsea Hewitt
Global innovation activation leader, Johnson & Johnson Innovation

Chelsea Hewitt is the Global Innovation Activation Leader for Johnson & Johnson Innovation (JJI). In this role, Chelsea oversees the strategy and implementation of outreach and engagement efforts to build a strong innovation network for JJI, JLABS, and JJDC. Before joining the Johnson & Johnson Innovation team, Chelsea was Director of Marketing and New Ventures at Prescience International where she led the strategic marketing, corporate partnerships and business development functions. Before Prescience, Chelsea was an analyst at a London-based investment firm providing diligence for investment strategies and prospective portfolio companies as well as for the development and assessment of internally generated projects in the company’s internal incubator, Illuminator Plc.

Keith LendenKeith Lenden, M.B.A.
Venture Partner, ARCH Venture Partners

Keith Lenden joined ARCH in 2017 as a Venture Partner. Keith is a seasoned entrepreneur and leader in the biotechnology and pharmaceutical space. Keith is a co-founder of Receptos, Inc. and Abide Therapeutics, Inc. and has served in a wide range of executive and product leadership roles at Esperion Therapeutics, Inc., Maxygen, Inc., Acologix, Inc. and Genteric, Inc. Keith started his career in biotechnology as a consultant at LEK Consulting. Keith earned a M.B.A. from the Haas School of Business at the University of California, Berkeley and A.B. and B.E. degrees from the Thayer School of Engineering at Dartmouth College. Keith is also a Kauffman Fellow.

Irving LevinIrving Levin, M.B.A.
Executive Chair and Founder, Genesis Financial Solutions and Chair, Digital Divide Data

Irving Levin is a serial entrepreneur, angel investor and mentor to the leadership of small private companies, and active in philanthropy. He earned both a B.A. in History and M.B.A. from the University of Chicago. He currently is Executive Chair and Founder of Genesis Financial Solutions, and the Chair of Digital Divide Data, an international social enterprise. He serves as well on the boards of a number of private companies and non-profit organizations. He and his wife Stephanie Fowler are Co-Trustees of The Renaissance Foundation. He has four children (including one currently in medical school at OHSU), and is an ex-professional but still pretty serious cellist.

Jay ParrishJay Parrish, Ph.D.
Chief Business Officer, Vir Biotechnology 

Dr. Parrish is Chief Business Officer at VIR. Previously he worked at Gilead Sciences, Inc. on the Corporate Development team, where he was involved in building Gilead’s oncology and infectious disease portfolio, ultimately leading infectious disease business development for the company. In the Corporate Development role, Dr. Parrish gained significant experience with search and evaluation, negotiations and transactions including in-licensing, out-licensing and M&A deals. Previously, he worked in Gilead’s Medicinal Chemistry group where his research focused on the discovery of small molecule anti-virals for the treatment of HIV, hepatitis C, and respiratory syncytial viruses. In this role, he was involved with several successful discovery campaigns, including being a co-inventor of ledipasvir (Harvoni®), approved as a cure for hepatitis C genotypes 1, 4–6. In 2015 Harvoni® had over $10 billion in sales worldwide, making it one of the most successful commercial drugs in history. Dr. Parrish holds a B.S. in chemistry from Emory University and a Ph.D. in synthetic organic chemistry from the University of South Florida. He completed a postdoctoral fellowship at the Scripps Research Institute and received an M.B.A. from U.C. Berkeley’s Haas School of Business.


Alternative Funding for Innovation and Startup Companies

Mark AllegrettaMark Allegretta, Ph.D.
Associate Vice President of Commercial Research, National Multiple Sclerosis Society

Dr. Allegretta is the Associate Vice President of Commercial Research at the National MS Society, whose responsibilities include providing leadership for the Society's commercial research programs and portfolio, including partnerships developed through Fast Forward. Most recently he was Chief Scientific Officer of BioMosaics Inc. Prior to that he worked in various positions at InterMune Pharmaceuticals and Connetics Corporation. Mark earned his Ph.D. in Cellular and Molecular Biology from the University of Vermont and was the recipient of a National MS Society postdoctoral fellowship at Stanford University.

Allison FormalAllison Formal, M.B.A.
Entrepreneur in Residence, UCLA

Ms. Formal is currently an Entrepreneur in Residence at UCLA and a successful business development and venture philanthropy consultant for non-profits, biopharmaceutical companies and academic medical centers. As VP Research Business Development at The Leukemia & Lymphoma Society, Ms. Formal helped to build the successful venture philanthropy arm, the Therapy Acceleration Program. Ms. Formal created more than 60 partnerships with industry providing non-dilutive tranche funding to biopharmaceutical companies developing therapies and diagnostics aimed at changing the standard of care for blood cancer. One of Ms. Formal's proudest accomplishments was working directly with Dr. Brian Druker and his team to create, fund and implement the strategic plan for Beat AML. This pre-clinical initiative started in 2013, began as a multi-sector partnership between the Knight Cancer Institute, biopharmaceutical companies, academic medical centers, and LLS. The work of this program is still ongoing and has created the foundation for what is now the clinical aspect of Beat AML, an ongoing master trial. Ms. Formal earned her M.B.A. in finance and marketing from Marymount University. 

Matt HepburnMatt Hepburn, M.D.
Program Manager, DARPA

Colonel Hepburn joined DARPA as a program manager in 2013. He aims to address the dynamic threats of emerging infectious diseases with potential impact on national security. Prior to joining DARPA, Colonel Hepburn served as the Director of Medical Preparedness on the White House National Security Staff. Additional previous assignments include: Chief Medical Officer at a Level II medical facility in Iraq, clinical research director at the US Army Medical Research Institute for Infectious Diseases, exchange officer to the United Kingdom and internal medicine chief of residents at Brooke Army Medical Center at Fort Sam Houston, Texas. Colonel Hepburn completed internal medicine residency and infectious diseases fellowship programs at Brooke Army Medical Center. He holds Doctor of Medicine and Bachelor of Science in biomedical engineering degrees from Duke University.

Lawrence MayerLawrence Mayer, Ph.D.
Senior Vice President, Translational Development, Jazz Pharmaceuticals and Co-Founder, Celator Pharmaceuticals

Dr. Mayer has played a lead role in the discovery and development of a number of oncology drugs, several of which achieved market approval. He held senior management positions at The Canadian Liposome Company and QLT Inc. before joining the BC Cancer Agency, where he established and directed the Health Canada accredited Investigational Drug Program. Dr. Mayer was Co-founder, President & CSO of Celator Pharmaceuticals which was formed in 2000 as a spin-out of Dr. Mayer's laboratory at the BC Cancer Agency. Celator was acquired by Jazz Pharmaceuticals in July, 2016 after the successful Phase 3 outcome with its lead leukemia product CPX-351. Dr. Mayer has authored more than 250 scientific publications and has more than 35 patent families awarded or pending.  


Closing Keynote

Gerry Langeler Gerry Langeler, M.B.A.
Managing Director and Venture Capitalist, OVP Venture Partners
For 25 years, Gerry has served as Managing Director for OVP Venture Partners, focusing on investments in the clean tech, communications and software sectors, backing over 125 early-stage startups. Prior to joining OVP, Gerry was co-founder of Mentor Graphics Corporation in Portland, OR in 1981. There he served as President, and over 11 years helped lead Mentor through its IPO to over $400M in worldwide sales and over $1B in market capitalization. Gerry currently serves on the Board of Directors of CradlePoint, Group14, Polysync, and Novomer. He is also the author of The Success Matrix - Winning in Business and in Life, and The Vision Trap (Harvard Business Review). In 2012, he was appointed to the Oregon Growth Board where he serves as co-chair. Gerry holds a B.A. in Chemistry from Cornell University and an M.B.A. from Harvard University.


Closing Remarks

John HunterJohn Hunter, M.D., F.A.C.S.
Chief Clinical Officer, School of Medicine, OHSU

Dr. John Hunter attended Harvard College, where he graduated with a degree in English Literature, and then attended medical school at the University of Pennsylvania. His surgical residency took place at the University of Utah, and he did fellowships in surgical endoscopy at the Massachusetts General Hospital and the University of Western Ontario. Following his fellowships, Dr. Hunter returned to Utah in 1988 to start the surgical endoscopy and minimally invasive surgery program at the University. In 1992, he relocated to Emory University in Atlanta, where he served as Chief of GI surgery and Vice Chair of Surgery (clinical). Nine years later, in 2001, Dr. Hunter traveled to OHSU where he assumed his present position as Mackenzie Chair of Surgery and Surgeon in Chief of the OHSU health system. Currently, he serves as the Chair of the American Board of Surgery. Internationally, Dr. Hunter is a member of the Executive Committee of the International Society of Surgery. He is also the Editor in Chief of the World Journal of Surgery, a post he has held for the last 12 years. He is currently serving as the Chief Clinical Officer of the OHSU School of Medicine.


Thursday, September 14

7:30 - 8:30 a.m.
8:30 - 9:00 a.m.
Opening remarks

Abhijit Banerjee, Ph.D., M.B.A. I Senior Director, Business Development, OHSU

Daniel Dorsa, Ph.D. I Senior Vice President of Research, OHSU

Elena Andresen, Ph.D. I Executive Vice President and Provost, OHSU

Brendan Rauw, M.B.A, C.L.P. I Vice President, Technology Transfer and Business Development, OHSU

9:00 - 9:45 a.m.
Opening Keynote
Becoming digital industrial
William Ruh , M.S. I Chief Executive Officer of GE Digital, Senior Vice President and Chief Digital Officer of GE
9:45 - 10:45 a.m.
Executive Panel: Breakthrough innovations transforming healthcare
Brian Druker, M.D. I Director, Knight Cancer Institute, OHSU and Associate Dean, School of Medicine — Oncology, OHSU

Harry Glorikian, M.B.A. (Moderator) I General Partner, New Ventures

John C. Hill, Jr., M.S.E.E.
 I General Manager of operations and COO of Imaging, GE Healthcare

Brian Lawrence, Ph.D., M.S. I Senior Vice President and Chief Technology Officer, Hill-Rom

Nick Pliam, M.D., Ph.D. I Venture Partner, Decheng Capital

10:45 - 11:00 a.m.
11:00 - 12:00 p.m.
Breakout session

Session 1: Role of molecular imaging in the era of personalized medicine

Session 2: Pharma's transition from internal R&D to external collaborations

Session 3: Women's contributions to innovation in science and business

Session 1:

Joe Gray, Ph.D. I Director, Center for Spatial Systems Biomedicine, OHSU and Associate Director for Biophysical Oncology, Knight Cancer Institute, OHSU

Christine H. Lorenz, Ph.D. I Vice President, Research and Clinical Collaborations, Siemens Medical Solutions USA

William Rooney, Ph.D. (Moderator) I Director and Professor, Advanced Imaging Research Center, OHSU

Carsten Shultz, Ph.D. I Chair, Department of Physiology and Pharmacology, OHSU and Group leader and scientist, European Molecular Biology Laboratory

Session 2:

Kanad Das, Ph.D. (Moderator) I Director, Business Development and Licensing, Merck

Melissa M. Fitzgerald, Ph.D. I Senior Director, Global Scouting, Pfizer

Nick Saccomano, Ph.D. I Chief Scientific Officer, Array BioPharma

Peter Sandor, M.D., M.D.S., M.B.A. I Vice President and head of oncology therapeutic area in Marketing Strategy, Astellas

Session 3: 

Jennifer Fox, Ph.D. (Moderator) I Executive Director, Oregon Translational Research and Development Institute (OTRADI)

Sancy Leachman, M.D., Ph.D. I Professor and Chair, Department of Dermatology, OHSU

Usha Pillai, Ph.D., P.M.P., M.S. I Founder and President, Aria Management Consulting, LLC. 

Christi Shaw, M.B.A. I Senior Vice President and President, Lilly Bio-Medicines

12:00 - 12:45 p.m.
12:45 - 2:00 p.m.
Company pitches

Matthew Johnson I General Manager and Executive Officer, APDM 

Erik Tucker, Ph.D. I Co-founder and Chief Operating Officer, Aronora

Frank Oliver I Chief Executive Officer, Server Dome

David Huang, M.D., Ph.D. I Founder, GoBiquity Mobile Health

Mark Slifka, Ph.D. I President and Chief Scientific Officer, Najít Technologies, Inc.

Andrew Watson, Ph.D., C.L.P. (Moderator) I Senior Director, Technology Transfer, OHSU

2:00 - 2:30 p.m.
2:30 - 3:30 p.m.
Collaboration pitches

Session 1: Marketing and branding: Go-to-market strategies for innovations

Session 2: Creating partnerships with investors

Session 3: Alternative funding for innovation and startup companies
Session 1:

Chris Conley (Moderator) I Partner, Heritage Partners

Christine Dumas
 I Consumer health and lifestyle reporter/strategic consumer trends advisor/author

Dennis Ford I Founder and Chief Executive Officer, Life Science Nation

Ann Mukherjee I Global Chief Marketing Officer, S.C. Johnson & Son


Session 2: 

James E. Burden, J.D. I Co-Founding Principal, Par Equity USA

Keith Lenden, M.B.A. (Moderator) I Venture Partner, ARCH Venture Partners

Irving Levin I Executive Chair and Founder, Genesis Financial Solutions and Chair, Digital Divide Data

Chelsea Hewitt I Global innovation activation leader, Johnson & Johnson Innovation

Jay Parrish, Ph.D., M.B.A. I Senior Vice President, Corporate Development, Vir Biotechnology, Inc.

Session 3:

Mark Allegretta, Ph.D. I Associate Vice President of Commercial Research, National Multiple Sclerosis Society

Allison Formal, M.B.A. (Moderator) I Entrepreneur in Residence, UCLA

Matt Hepburn, M.D. I Program Manager, DARPA

Lawrence Mayer, Ph.D. I Senior Vice President, Translational Development, Jazz Pharmaceuticals and Co-Founder, Celator Pharmaceuticals

3:30 - 3:45 p.m.
3:45 - 4:30 p.m.
Closing keynote
"The Success Matrix"

Gerry Langeler, M.B.A. I Managing director and Venture Capitalist, OVP Venture Partners

4:30 - 4:45 p.m.
Closing Remarks

John Hunter, M.D., F.A.C.S. I Chief Clinical Officer, School of Medicine, OHSU

4:45 - 7:00 p.m.
Networking Reception

* Topics and times are subject to change

Getting to the conference


CLSBCollaborative Life Sciences Building (CLSB)
2730 SW Moody Avenue
Portland, Oregon 97201
View in Google Maps 



Here are some helpful maps and links based on your transportation needs: 

Car >

Portland Streetcar >

TriMet Bus >



Convenient parking options are available near the CLSB. Attendees may park in the OHSU Schnitzer parking lot, just north of the CLSB, (The address for the parking lot is: 2650 SW Moody, Portland, OR 97201) or in the CLSB parking garage located below the building with an entrance located on the north end of the building (near the Skourtes Tower, where SW Meade meets SW Moody Ave.).